Tvardi develops oral small molecule drugs that inhibit STAT3 to treat inflammatory and proliferative diseases. TVRD reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 8 | LUCID CAPITAL MARKETS | Assumed coverage | Buy | |
| Jul 30 | BTIG | Target lowered | Buy | |
| Jul 8 | Raymond James | Upgrade | Buy | |
| Jul 7 | BTIG | Reiterated | Buy | |
| Jun 8 | HC Wainwright & Co. | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in TVRD in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TVRD is in one of them and how their past TVRD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TVRD in an article yet. Here's the latest on the wider market.
About Tvardi Therapeutics
Tvardi is a biopharmaceutical company based in Sugar Land, Texas. It is developing oral, small molecule drugs that aim to block STAT3, a protein inside cells that drives inflammatory and cell growth diseases. Its TTI-101 candidate is being tested in patients with liver cancer and has also been studied in idiopathic pulmonary fibrosis, a lung disease. The company does not yet sell products, and its drugs are still in clinical trials.
- Headquarters
- Sugar Land, TX